- Home
- FMAO vs AVIR Comparison
FMAO vs AVIR Comparison
Compare FMAO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- AVIR
- Stock Information
- Founded
- FMAO 1897
- AVIR 2012
- Country
- FMAO United States
- AVIR United States
- Employees
- FMAO N/A
- AVIR N/A
- Industry
- FMAO Savings Institutions
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- FMAO Finance
- AVIR Health Care
- Exchange
- FMAO Nasdaq
- AVIR Nasdaq
- Market Cap
- FMAO 347.3M
- AVIR 273.0M
- IPO Year
- FMAO N/A
- AVIR 2020
- Fundamental
- Price
- FMAO $28.19
- AVIR $3.74
- Analyst Decision
- FMAO Hold
- AVIR Hold
- Analyst Count
- FMAO 1
- AVIR 1
- Target Price
- FMAO $26.00
- AVIR $6.00
- AVG Volume (30 Days)
- FMAO 18.1K
- AVIR 413.9K
- Earning Date
- FMAO 07-31-2025
- AVIR 08-06-2025
- Dividend Yield
- FMAO 3.14%
- AVIR N/A
- EPS Growth
- FMAO 26.69
- AVIR N/A
- EPS
- FMAO 2.01
- AVIR N/A
- Revenue
- FMAO $104,144,000.00
- AVIR N/A
- Revenue This Year
- FMAO N/A
- AVIR N/A
- Revenue Next Year
- FMAO $6.16
- AVIR N/A
- P/E Ratio
- FMAO $14.02
- AVIR N/A
- Revenue Growth
- FMAO 9.24
- AVIR N/A
- 52 Week Low
- FMAO $20.88
- AVIR $2.46
- 52 Week High
- FMAO $34.15
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- FMAO 68.85
- AVIR 75.75
- Support Level
- FMAO $25.01
- AVIR $3.43
- Resistance Level
- FMAO $27.16
- AVIR $3.80
- Average True Range (ATR)
- FMAO 0.92
- AVIR 0.14
- MACD
- FMAO 0.33
- AVIR 0.03
- Stochastic Oscillator
- FMAO 99.76
- AVIR 78.46
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).